Stocktoria
Design Therapeutics, Inc. DSGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-03-26
Design Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| R&D expense | $59.1M | $44.4M | $57.1M | $48.6M | $24.8M |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | -$35.5M |
| EPS (diluted) | $-1.22 | $-0.88 | $-1.19 | $-1.14 | $-0.77 |
| Operating cash flow | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M |
| Free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M | -$30.9M |
| Cash & equivalents | $16.9M | $22.6M | $21.2M | $26.5M | $298.6M |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M |
| Shareholders' equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M |
Source: SEC EDGAR filings · CIK 0001807120 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.